2nd Indonesian Conference on Clinical Pharmacy (ICCP), Sanur, Bali-INDONESIA, 27-28 th October 2016

EFFECTIVENESS OF THERAPY AND QUALITY SERVICES IN

HYPERTENSIVE AND DIABETIC PATIENTS
AMONG JKN AND NON-JKN HEALTHCARE
SWASTINI DA1*, WIRYANTHINI IA2, SARAH AP1
1
Biomedic and Clinical Pharmacy, Departement of Pharmacy Udayana University
2
Medical Departement, Udayana University
Corresponding author: devayuswastini@yahoo.co.id

BACKGROUND b. The Ability to Reduced Blood Preasured

Hypertension and Diabetes Mellitus Type II are chronic diseases with AMLODIPINE VALSARTA
high prevalace and resulting high cost treatment. The principle of
“cost-effective” by National Health Insurance Program (JKN)
awareness patients, they will receives less compherensive benefits
compared to general patients. The experiment was conducted to
compare JKN against Non-JKN in term of outcome and quality of
services by heald care provider.

METHOD
Sample Amlodipine and Valsartan have same value to reduce
Interna Outpatient blood pressured in hypertensiv patients among JKN and
Passed Department Non-JKN helath care
the inclusions and
exclusions criteria c. Present of Adverse Drug Reaction
Outcome Quality of ADR
Therapy Services 25.00%

20.00%

15.00%

10.00%
JKN
blood glucose 5.00%
Non-JKN
ADR Questionnaire 0.00%
pressured leves Hypo-
gly-
Nausea Vomiting Diarrhea

caemia

d. Quality of Services
Servqual
Paired t-test followed by Servqual Type N Mean ±SD Score` P Value
% ADR
independent t-tes (p<0,05) score Tangible
JKN 36 3.55±0.785 -0.65
0.102
Non-JKN 36 3.51±0.674 -0.65
JKN 36 3.27±0.764 -0.54
Reability 0.206
Non-JKN 36 3.12±0.967 -0.46
RESULT Responsiveness
JKN 36 3.25±0.123 -0.77
0.053
Non-JKN 36 3.46±0.967 -0.68
The result
a. The Ability in Reducing Blood Glucose Levels Assurance
JKN 36 2.92±0.751 -.051
0.107 show that p
Non-JKN 36 2.56±0.665 -.041
Random selection technique was used to select 72 patients, 36 JKN JKN 36 3.22±0.345 -0.67 Value >
Emphaty 0.052
and 36 Non-JKN devided equal both diabetic and hypertensiv Non-JKN 36 3.01±0,789 0.58 0.05
patient, which has been confirmed passed the inclusions and CONCLUSION
exclusions during the period of October 2015 to March 2016.
 There’s greater reduction of blood glucose levels with lower
insidences of ADR in Diabetic JKN patients compared to Non-
Fasting Blood Glukose Level Postprandial Blood Glucose Level
350 400
JKN. Meanwhile there’s no significant outcome therapy with
300 350 zero ADR between JKN and Non-JKN in Hypertensiv patients.
250
300
 There’s no significant difference in quality services among
250
JKN and Non-JKN Health Care
mg/dl

200
Before
200
Before
150 After 164
155.06
mg/dl

After

REFERENCES
deviation 150
120 118.87
deviation
100
100

50
50
American Association of Clinical Endocrinologists. 2011. Medical Guideline for
Clinical Practice for Developing A Diabetes Mellitus Comprehensive Care
0

in e d
0
Plan. Amerika: American Association of Clinical Endocrinologists. pp: 6,
ag zi ron
in

ge

m a 11.
or c
zi

ro
rm

h k i
ha

li
a

f
ic

et op m
lik
fo

m
op

G a
c Di
et

Katzung, B. G. 2006. Basic and Clinical Pharmacology. Ninth Edition. New

ia

m lu
c
m

D
lu

G
G

York: McGraw Hill.

Kim, J. K. dan W. S. Han. 2012. Improving service quality in long-term care
Both metformin and glicazid (JKN antidiabetic drug), have a greater hospitals: national evaluation on long-term care hospitals and employees
value,and its significant to reduce fasting and pospandrial blood perception of quality dimensions. Osong Public Health Res Perspect. Vol.
3(2): 94-99.
glucose levels compare to glucophage and diamicron (Non JKN Undang-undang No.40. 2004. Sistem Jaminan Sosial Nasional SJSN).Jakarta
antidiabetic drug), at p<0.05. Depkes RI.